Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.39 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | SDCBP | O00560 | 1/20 | 0.32 |
| ▸ | SDC2 | P34741 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245164 | 0.86 | RAB9A (0.36) | MTNR1AMTNR1BMAPTNPC1RAB9A | |
| SCHEMBL4427391 | 0.83 | MTNR1A (0.35) | MTNR1AMTNR1BMAPTNPC1RAB9A | |
| SCHEMBL6193808 | 0.79 | MAT2A (0.35) | L3MBTL1DGAT2 | |
| SCHEMBL4426670 | 0.76 | MTNR1A (0.66) | MTNR1AMTNR1BMAPT | |
| SCHEMBL4437300 | 0.76 | MTNR1A (0.44) | MTNR1AMTNR1BACACBMAPTNPC1 | |
| SCHEMBL4427389 | 0.73 | MTNR1A (0.46) | MTNR1AMTNR1BMAPT | |
| SCHEMBL3245599 | 0.71 | MTNR1A (0.44) | MTNR1AMTNR1BMAPT | |
| Dimethylamine SCHEMBL3253647 | 0.71 | MTNR1A (0.39) | MTNR1AMTNR1BMAPTNPC1RAB9A | |
| SCHEMBL4430578 | 0.70 | MTNR1A (0.44) | MTNR1AMTNR1BACACBMAPT | |
| SCHEMBL3245161 | 0.70 | MTNR1A (0.46) | MTNR1AMTNR1BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537113-A1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Suven Pharmaceuticals Ltd. (IN) | 2005-06-08 | — | — | EP | claimed |
| WO-2004000845-A1 | ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | claimed |
| EP-1537113-B1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | EP | disclosed |
| US-7297711-B2 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-11-20 | — | — | US | disclosed |
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | disclosed |
| EP-1537113-A1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Suven Pharmaceuticals Ltd. (IN) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004000845-A1 | ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | TPH1, HTR1A, HTR7 | MTNR1A 76/4885MTNR1B 105/4885ACACB 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.